Robotic stereotactic body radiation therapy for liver-limited malignant tumors

Purpose. To study the influence of PD-L1 expression on the dynamics of immunological changes before and at different intervals after stereotactic body radiation therapy (SBRT) of metastatic lesions in patients with metastatic forms of solid tumors. Materials and methods. A quantitative assessment and analysis of blood immunological parameters was conducted before irradiation, via 3-4 weeks and via 6-8 weeks after SBRT in patients with malignant tumors with oligometastases in the liver or lungs, in groups with negative and positive expression of PD-L1. All peripheral blood samples were analyzed by flow cytometry. Statistical analysis was performed using Friedman and Nemenyi criteria. Results. 3-4 weeks after the end of SBRT in group CPS <1 we observed statistically significant increase of activated T-helpers (CD3+CD4+HLA-DR+), activated cytotoxic T-lymphocytes (CD3+СD8+HLA-DR+), T-lymphocytes (CD3+CD19-) and T-helpers (CD3+CD4+). Wherein, activated T-helpers and activated cytotoxic T-lymphocytes statistically significantly increased 6-8 weeks after SBRT compared with the study before irradiation. In group CPS> 1, we revealed statistically significant increase of activated T-helpers 6-8 weeks after and decrease of T-regulatory lymphocytes (CD4+CD25brightCD127low) 3-4 weeks after completion of SBRT compared with the study before radiotherapy. When we analyzed the indicators by the TPS index, most of the statistically significant changes were recorded in the group with negative expression (TPS <1): increasing of activated T-helpers and activated cytotoxic T-lymphocytes 3-4 weeks and 6-8 weeks after SBRT and decreasing of T-regulatory lymphocytes 3-4 weeks after irradiation compared with the study before irradiation. Conclusion. Groups with negative PD-L1 expression (CPS <1 and TPS <1) are associated with a more activated antitumor T-cell immune response compared to patients with positive PD-L1 status (CPS≥1 and TPS≥1), however, further researches are needed.

Download Full-text

The Dosimetric Effects of Photon Energy on the Quality of Volumetric Modulated Arc Therapy for Lung Stereotactic Body Radiation Therapy

World Journal of Oncology Research ◽

10.15379/2413-7308.2016.03.04 ◽

2016 ◽

Vol 3 ◽

pp. 27-35

Author(s):

Leila Tchelebi

Keyword(s):

Radiation Therapy ◽

Photon Energy ◽

Stereotactic Body Radiation Therapy ◽

Volumetric Modulated Arc Therapy ◽

Stereotactic Body Radiation ◽

Arc Therapy

Download Full-text

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

Case Medical Research ◽

10.31525/ct1-nct03889119 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Radiation Therapy ◽

Stereotactic Body Radiation Therapy ◽

Stereotactic Body Radiation

Download Full-text

Faculty Opinions recommendation of Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717597818.793152991 ◽

2012 ◽

Author(s):

Mitesh Borad

Keyword(s):

Hepatocellular Carcinoma ◽

Radiation Therapy ◽

Transarterial Chemoembolization ◽

Stereotactic Body Radiation Therapy ◽

Salvage Treatment ◽

Stereotactic Body Radiation

Download Full-text

Faculty Opinions recommendation of Stereotactic body radiation therapy (SBRT) for early-stage lung cancer in the elderly.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734120948.793574022 ◽

2020 ◽

Author(s):

Lorenzo Livi ◽

Isacco Desideri

Keyword(s):

Lung Cancer ◽

Radiation Therapy ◽

Stereotactic Body Radiation Therapy ◽

Early Stage ◽

The Elderly ◽

Early Stage Lung Cancer ◽

Stereotactic Body Radiation ◽

Stage Lung Cancer

Download Full-text

Faculty Opinions recommendation of Local failure after stereotactic body radiation therapy or wedge resection for colorectal pulmonary metastases.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736306894.793566938 ◽

2019 ◽

Author(s):

Paul Van Schil

Keyword(s):

Radiation Therapy ◽

Stereotactic Body Radiation Therapy ◽

Pulmonary Metastases ◽

Wedge Resection ◽

Local Failure ◽

Stereotactic Body Radiation

Download Full-text

Non-surgical Treatments for Lung Metastases in Patients with soft Tissue Sarcoma: Stereotactic Body Radiation Therapy (SBRT) and Radiofrequency Ablation (RFA)

Current Medical Imaging Formerly Current Medical Imaging Reviews ◽

10.2174/1573405616999200819165709 ◽

2020 ◽

Vol 16 ◽

Author(s):

Cecilia Tetta ◽

Maria Carpenzano ◽

Areej Tawfiq J Algargoush ◽

Marwah Algargoosh ◽

Francesco Londero ◽

...

Keyword(s):

Overall Survival ◽

Radiation Therapy ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Stereotactic Body Radiation Therapy ◽

Lung Metastases ◽

Disease Free Interval ◽

Stereotactic Body Radiation ◽

Free Interval ◽

Disease Free

Background: Radio-frequency ablation (RFA) and Stereotactic Body Radiation Therapy (SBRT) are two emerging therapies for lung metastases. Introduction: We performed a literature review to evaluate outcomes and complications of these procedures in patients with lung metastases from soft tissue sarcoma (STS). Method: After selection, seven studies were included for each treatment encompassing a total of 424 patients: 218 in the SBRT group and 206 in the RFA group. Results: The mean age ranged from 47.9 to 64 years in the SBRT group and from 48 to 62.7 years in the RFA group. The most common histologic subtype was, in both groups, leiomyosarcoma. : In the SBRT group, median overall survival ranged from 25.2 to 69 months and median disease-free interval from 8.4 to 45 months. Two out of seven studies reported G3 and one G3 toxicity, respectively. In RFA patients, overall survival ranged from 15 to 50 months. The most frequent complication was pneumothorax. : Local control showed high percentage for both procedures. Conclusion: SBRT is recommended in patients unsuitable to surgery, in synchronous bilateral pulmonary metastases, in case of deep lesions and in patients receiving high-risk systemic therapies. RFA is indicated in case of a long disease-free interval, in oligometastatic disease, when only the lung is involved, in small size lesions far from large vessels. : Further large randomized studies are necessary to establish whether these treatments may also represent a reliable alternative to surgery.

Download Full-text